Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Tax Withholding Transaction
SEC Form 4 Filing
Chief Scientific Officer of Fulgent Genetics, Gao Hanlin, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On October 26, 2024, Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc., had 1,639 shares of common stock withheld to satisfy tax obligations.
- The shares were withheld at a price of $19.42 per share.
- Following the transaction, Gao Hanlin directly owns 921,418 shares of Fulgent Genetics, Inc.
- The tax withholding was related to the vesting of restricted stock units granted on November 7, 2022.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations, so the sentiment is neither positive nor negative.
Industry Context
Form 4 filings are a routine part of compliance for company insiders and provide transparency into their transactions in the company's stock. This transaction is related to tax obligations arising from vested stock awards, a common occurrence.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine tax withholding.
Key Dates
| Date | Description |
|---|---|
| 2022-11-07 | Date of restricted stock units grant to Gao Hanlin. |
| 2022-11-09 | Date of original Form 4 filing reporting the restricted stock units grant. |
| 2024-10-26 | Date of the tax withholding transaction. |
| 2024-10-29 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.